BOSTON, MA—The SGLT2 inhibitor remogliflozin etabonate (Remo) might help improve fibrosis stage, according to a post-hoc analysis presented at The Liver Meeting® 2016. “Remo improves insulin ...
Japanese researchers reveal an association between elevated FIB-4 index 24 weeks after the initiation of nucleos(t)ide analogue (NA) therapy and the development of hepatocellular carcinoma (HCC) in ...
Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet in Sweden ...
Please provide your email address to receive an email when new articles are posted on . Results showed 10.3% of veterans had a FIB-4 score greater than 2.67 and 5.3% had a score greater than 3.25. A ...
Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with chronic hepatitis B without cirrhosis, the risk for hepatocellular carcinoma was ...
A new risk score for HCC risk in non-viral hepatitis or cirrhosis patients improves detection by 22.9%. The model uses FIB-4, age, sex, race, BMI, diabetes, smoking, and alcohol use for risk ...
Repeat fibrosis-4 (FIB-4) scores can be used to identify people at greatest risk for cirrhosis of the liver, new research shows. "Done repeatedly, this test can improve prediction capacity to identify ...
Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study. The risk of liver cirrhosis increases if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results